Kristen Marks, MD, MS

Associate Professor
Weill Cornell Medicine
New York, NY, United States

Dr. Marks is an Associate Professor of Medicine at Weill Cornell Medicine (WCM) where she conducts clinical trials related to HIV, HCV and COVID prevention and treatment. She received Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (Cornell), where she focused clinical training and research on HIV and hepatitis virus infections and completed Weill Cornell's Master's Degree in Clinical Investigation.

She serves as a co-director of the Cornell HIV/AIDS Clinical Trials Unit, where she conducts several treatment studies related to HIV and hepatitis viruses. She previously served as co-chair of IDSA/AASLD’s joint guidelines panel for “Recommendations for testing, managing and treating hepatitis C” and as a member of New York State’s HCV guidelines panel. When the COVID pandemic hit New York City, she led the phase 3 studies of remdesivir at Weill Cornell and continues to lead the phase 3 studies of vaccines for the prevention of COVID at Weill Cornell.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• LB749 - High HBsAb Seroprotection Achieved 4 Weeks after 3 doses of HepB-CpG Vaccine in People Living with HIV (PLWH) without Prior HBV Vaccination (ACTG A5379 Group B Preliminary Results)

  Thursday, October 20, 2022
  2:33 PM – 2:45 PM US ET